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mortality depends on epidemiological evidence relating reduced risk to HAQ improve-
ment.. Costs and utilities associated with different HAQ levels were based on data 
from cohort studies and cross-sectional surveys in Italy. RESULTS: In the base case    
scenario (10% of patients treated in each disease state) we estimated that treatment 
with any biologic had an incremental cost of 26.4% over 10 years (including only            
direct costs). By analysing each disease state separately, costs vary from 22.3% to            
28.3%. The inclusion of potential avoided nursing home admissions and indirect          
costs/lost employment further improved the cost-effectiveness ratio. The model shows 
that a higher percentage of treated patients with a HAQ score between 1.1 and 2.6 
improves the cost-effectiveness ratio. The greater effectiveness of biological agents      
contribute to maintaine patients in less severe disease states by favoring disease 
improvement and remission; this signiﬁcant health beneﬁt is also reﬂected on mortality 
rate. Sensitivity analyses showed long-term HAQ progression with biologic therapies         
and discounting as most sensitive variables. CONCLUSIONS: Our results suggest that    
biologic therapies are cost-effective when compared with DMARDs. The model is 
further suitable for use in a wide range of other cost-effectiveness questions in rheu-
matoid arthritis. It appears to accurately capture disease progression and its effects 
and can therefore be useful for estimating cost-effectiveness of new treatments in RA 
in different Italian health care settings.
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OBJECTIVES: To evaluate the annual economic impact of biotherapies for the treat-
ment of RA patients. METHODS: Target population was deﬁned as adults belonging 
to RA medical Diagnosis Related Group (DRG) in the French national database of 
the Information System Program Management (PMSI) in hospital. The total direct 
costs considered were: treatment costs (current published prices, April 2009), hospi-
talization costs including administration cost in hospital (DRG, V11 March 2009), 
and for ambulatory patients the rheumatologist follow-up and subcutaneous injection 
costs. Treatment cost was calculated according to treatment dose, length and duration 
as reported in real life data. Real life data were based on a registry (AIR PR) and 
record from market analysis (A  A panel study March 2008). Biotherapies market 
share data were issued from the GFK Performance Tracker (Q3 2008). RESULTS: A 
total of 15,873 patients were identiﬁed in 2007 with biotherapies of Abatacept: 952 
(6), a19,618 (81), a18,676,336 (8); Adalimumab: 4762 (30),   a14,950 (patient injec-
tion) (99), a15,464 (nurse injection) (98), a71,252,500 (32); Etanercept: 5873 (37),   
a14,693 (patient injection) (99), a14,849 (nurse injection) (98), a86,575,567 (39); 
Inﬂiximab*: 2381 (15), a 12,144 (84), a28,914,864 (13); Rituximab**: 1905 (12),   
a 6,451 1 cycle (89) a12,789 2 cycles (90), a16,029,434 (7); Total: 15873 (100), NA,   
a221,448,701 (100) for Patients N (%), Annual costs / patient (% acquisition costs),          
Total annual costs (%).CONCLUSIONS: In real life setting annual RA treatment 
costs/patient in France varies from a6,451 to a19,618 depending on the biotherapy 
used. Drug acquisition cost represents the major part of the annual costs. The global 
annual cost is a221, 448, 701.
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BACKGROUND: Rheumatoid arthritis (RA) is a systemic autoimmune disease which 
affects about 0.5% of the population in developing countries. The current biologic 
DMARDs approved in Brazil as 1st line therapy are: inﬂiximab, etanercept, adalim-
umab (anti-TNF therapies), abatacept (T-cell co-stimulation therapy) or tocilizumab 
(IL-6 receptor antagonist). OBJECTIVES: To assess the budget impact of offering 
tocilizumab as an option to a pool of patients with rheumatoid arthritis (RA) in Brazil. 
METHODS: The perspective is private payer in Brazil. Only direct costs were consid-
ered which comprised of: drug, management and administrations costs [Scheinberg et 
al. 2005]. Drug costs were taken from public sources [Kairos magazine. May, 2009]. 
Base case dosages considered were: tocilizumab (8 mg/kg dosage each 4 weeks) and 
inﬂiximab {4.3 mg/kg (Ollendorf et al. 2005) at weeks 0, 2, 6 and every 8 weeks}, 
assuming a 70 kg patient, adalimumab (40 mg every other week), etanercept (50 mg 
every week) and abatacept (750 mg at weeks 0, 2, 4 and then every 4 weeks). The 
discount rate taken was 5% according to the Brazilian guidelines for Health Technol-
ogy Assessment (HTA) [Vianna et al. 2007] since a 5-year horizon was taken for this 
analysis. Both the treatment mix forecast and the tocilizumab penetration change were 
projected based on market research data. The results are expressed in 2009 Brazilian 
Reais (US$1 y $Brz2.5). RESULTS: Total annual costs were $Brz81,021 for tocili-
zumab, $Brz92,789 for etanercept, $Brz98,541 for adalimumab, $Brz105,283 for 
inﬂiximab and $Brz 85,020 for abatacept. Based on the change in the forecast;, a total 
savings for a period of 5 years were $Brz1,573,902 for each 100 treated patients, 
when comparing the group of patients received tocilizumab to the group of patients 
that did not receive tocilizumab. CONCLUSIONS: Findings suggest tocilizumab offers 
potential costs reductions in the private health care system in Brazil.
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OBJECTIVES: The aim of the analysis was to assess the impact on the Polish health 
care budget the ﬁnancing of Arava® within ambulatory reimbursement list compared 
to Arava® ﬁnancing within the National Health Fund rheumatoid arthritis therapeutic 
program; all costs were calculated from public payer’s perspective in Poland in a one-
year time horizon. METHODS: Direct medical costs regarding drug costs, diagnostic 
costs, ambulatory and hospital treatment valid from a public payer’s perspective were 
taken into account in the analysis. Ofﬁcial retail price of Arava® was obtained from 
Sanoﬁ-Aventis from Poland. Five reimbursement scenarios were taken into consider-
ation depending on reimbursement limits and levels of coverage by public payer. 
RESULTS: Introduction of Arava® on ambulatory reimbursement list results in incre-
mental savings between 4.4 million PLN and 6.4 million PLN (depending on reim-
bursement scenario) comparing to continuation of Arava® treatment within the 
rheumatoid arthritis therapeutic program from public payer’s perspective. Financing 
Arava® within reimbursement list could increase number of patients treated with a 
Arava® from around 4.3 thousands to 5,3 thousands (at present 3 thousands of 
patients are treated with leﬂunomide within therapeutic program) or extend duration 
of treatment with additional from 5 up to 9 months. CONCLUSIONS: Financing 
Arava® within ambulatory reimbursement list generates substantial savings for the 
public payer in Poland compared to ﬁnancing within a therapeutic program and pro-
vides treatment with Arava® for a greater number of patients with rheumatoid arthritis 
or extends the duration of treatment.
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OBJECTIVES: To describe the disease management and the cost of patients presenting 
a diagnosis of sciatica in the hospital perspective. METHODS: We performed a local 
data base request from the medical information system (PMSI) of the University Hos-
pital of Montpellier. We considered three consecutive years (2006, 2007, 2008) which 
allowed us to get a follow-up and a traceability of patients over this period. We ana-
lyzed a group of patients 18–50 years old admitted across acute care, day care or 
mid-term care sectors with the following diagnosis codes M 54, M 5415, M 5416 and 
M 5417 of the ICD-10. RESULTS: A total of 232 patients were selected over the 
period representing a total of 541 admissions (i.e. 2.3 admissions per patient). The 
mean o SD age was 39 o 8 years female represent 45% of the patients. We observed 
175 admissions in acute care (“less than 24 h” admissions excluded) with a mean 
length of stay of 7 o 5.2 days. Day-care represents 15.4% of admission in acute care 
sector. We observed 38 admissions in mid-term care with a mean length of stay of 3 
o 4.8 days. Few patients (3 %) were admitted consecutively in acute care and in mid 
term care thereafter. Surgery was the reason of ﬁrst admission for six patients. The 
cost is estimated at a2055 per patient admitted in an acute care sector. CONCLU-
SIONS: In our sample, we noted a high rate of admission per patient for diagnosis, 
medical treatment or physical therapy reasons as the main pattern of sciatica manage-
ment in-hospital. Admissions for surgery were marginal. Our ﬁgures are key informa-
tion to specify management of sciatica and transition probabilities in decision tree 
models. Thus, we would simulate the impact of innovative medical device on the 
burden of disease and disclose where are the most prominent societal beneﬁts.
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BACKGROUND: Rheumatoid arthritis (RA) is a systemic autoimmune disease which 
affects 0.5% of the population in developing countries. The current biologic DMARDs 
approved in Brazil as 1st line therapy are: inﬂiximab, adalimumab, etanercept, (anti-
TNF therapies) and abatacept (T-cell co-stimulation therapy) or tocilizumab (IL-6 
receptor antagonist). OBJECTIVES: To assess the budget impact of offering tocili-
zumab as an option to a pool of patients with RA in Brazil. METHODS: The perspec-
tive was from a public payer. Only direct costs were considered which comprised: 
drug, management and administrations costs [Scheinberg et al. 2005]. Base case 
dosages considered were: tocilizumab (8 mg/kg dosage each 4 weeks) and inﬂiximab 
[4.3 mg/kg (Ollendorf et al. 2005) at weeks 0, 2, 6 and every 8 weeks], assuming a 
70 kg patient, adalimumab (40 mg every other week), etanercept (50 mg every week) 
and abatacept (750 mg at weeks 0, 2, 4 and then every 4 weeks). We took the 
maximum price to government as a basis to all therapies [Jun, 2009]. The discount 
rate taken was 5% according to the Brazilian guidelines for (HTA) [Vianna et al. 
2007] and a 5-year horizon was assumed. Both the treatment mix forecast and the 
tocilizumab penetration change were projected based on market research data. The 
results are expressed in 2009 Brazilian Reais (US$ 1 y $Brz2.5). RESULTS: Total 
annual costs were $Brz47,566 for tocilizumab, $Brz50,785 for etanercept, $Brz53,909 
for adalimumab, $Brz58.603 for inﬂiximab and $Brz50,048 for abatacept. Based on 
the change in the mix of treatment forecast, a total savings for a period of 5 years 
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were $Brz674.527 for each 100 treated patients, when comparing the group of 
patients that received tocilizumab to the group of patients that did not receive tocili-
zumab. CONCLUSIONS: Findings suggest tocilizumab has the potential to offer costs 
reductions in the public health care system in Brazil.
PMS20
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OBJECTIVES: To develop a cost-effectiveness and budget impact analysis of intra-
articular sodium hyaluronate 25 mg/2.5 ml (SH) versus total knee arthroplasty (TKA) 
in the treatment of knee osteoarthritis grades II and III of Kellgren-Lawrence classiﬁca-
tion, in patients who failed conservative treatment, under the Brazilian public health 
care system (BPHS) perspective. METHODS: A Markov model was developed to 
project costs and outcomes associated with knee osteoarthritis progression in 3 years. 
In the model all patients were eligible to surgery and could either receive SH or 
undergo TKA immediately. SH could delay or cancel surgery. The cycle duration was 
3 months and the corresponding transition probabilities were obtained from the litera-
ture. The outcome was expressed as the number of avoided TKAs. The analysis con-
sidered only direct medical costs, including drugs, physician visits, procedures and 
complications treatment. Costs and outcomes were discounted at 5% per year. A 
budget impact analysis was developed considering the estimated number of TKAs in 
the BPHS in 2009. Main parameters were evaluated in a sensitivity analysis. RESULTS: 
In a 3-year time horizon, total costs per patient were US$3445 (2005-PPP-index 
USD1.0  R$1.4) for the SH group and R$4381 for the TKA group. The reduction 
in the absolute number of surgeries was 72.8% in the SH group, compared with TKA. 
Likewise, there was a cost reduction of US$936, in favor of SH. Considering 3991 
eligible patients in the public system, the total annual costs for SH and TKA groups 
were US$5,136,234 and US$17,484,003, respectively. As a result, the budget impact 
was US$12,347,769, in favor of SH. The sensitivity analysis about the time horizon 
showed a cost-saving result until 4 years. CONCLUSIONS: The use of SH after failure 
of conservative treatment in patients with grades II or III knee osteoarthritis showed 
to be effective, leading to a reduction in costs and number of surgeries.
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OBJECTIVES: To estimate the budget impact implied by the introduction of RTX 
after failure of one or more TNF a therapies for the French health care system. 
METHODS: A Markov model reproduced the course, over 4 years, of patients treated 
by either inﬂiximab, etanercept, adalimumab or RTX, after failure of one or more 
TNF a therapies. Markov states were composed of the 4 TNF a strategies. The success 
rate for each strategy (ACR20) was based on a bayesian mixed treatment comparisons 
model.Health care consumptions were estimated from an observational study con-
ducted retrospectively in 59 hospital rheumatology services (TC2 study). Three 
hypotheses were tested for the penetration of RTX into the market: RTX is not used 
(H1), RTX is used progressively (H2), RTX is the only treatment available (H3). As a 
sensitivity analysis, we applied coefﬁcients to health care resources in third line. 
RESULTS: The RTX target population is expected to be 5700 patients. Under H1, 
direct total medical costs are expected to be a47,180,000. Under H3 these costs reach 
a32,600,000, thus a decrease of 31% respectively compared to H1. Under H2, costs 
progressively decreased as RTX penetrates the market. The impact of multiplication 
coefﬁcients is important. At the beginning of the simulation, the difference between 
the base-case analysis (H2) and the worst case sensitivity analysis (coeff2  20%) 
 concerning the total direct medical costs reached a3,160,000 (respectively a47,560,000 
for H2 and a50,720,000 for H2–20%). However, while RTX progressively enters into 
the market, this difference decreases, attaining only a1,175,000 at the end of the simu-
lation. CONCLUSIONS: RTX is expected to produce important savings if used after 
failure of one or more TNF a therapies. This is due to the administration rhythm of 
this product, generally every 6 to 12 months.
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OBJECTIVES: To estimate the annual direct and indirect costs of psoriatic arthritis 
(PsA) in Spain, and to identify key cost drivers. METHODS: An observational study 
was undertaken at 18 Spanish centres. Sociodemographic characteristics and duration 
of the disease were collected from patient hospital clinical records, and PsA-related 
resources (a, year 2008 values) from patient notebooks. The following direct resources 
were collected: inpatient hospitalisations, surgeries, outpatient visits (specialists, 
general care physician, other health care professionals and alternative medicine), 
diagnostic procedures, laboratory tests, medication (prescription -including TNFalpha 
inhibitors administered at hospital- and non-prescription drugs paid by patients), 
hospital day-care facilities for the administration of biological therapies and photo-
therapy sessions. Indirect resources consisted of productivity losses (full or part-time), 
social assistance and out-of-pocket expenses paid directly by patients (formal caregiv-
ers, disease-related investments). RESULTS: Data were available on 287 patients with 
PsA. The mean age was 52.40 o 12.53 years, 55.7% were men, and the mean disease 
duration was 10.85 o 9.62 years. Of these patients, 24.7% had received biologic 
therapy during the study period. The average annual cost per patient with PsA was 
a6710 (95% conﬁdence interval [CI], a4949, a8584). Direct and indirect costs repre-
sented a5449 (95%CI, a4367–a6597, 81.2% of total costs) and a1261 (95%CI, 
a581–a1987, 18.8% of total costs), respectively. The most important categories of 
costs were for medication (a3,758, 95%CI, a3,338–a4,241, 56.0% of total costs), 
productivity losses (a1121, 95%CI, a551–a1692, 16.7% of total costs), visits (a750, 
95%CI, a507–a943, 11.2% of total costs), and hospital day visits (a306, 95%CI, 
a289–a324, 4.6% of total costs). CONCLUSIONS: Our data show that psoriatic 
arthritis is associated with a remarkable impact over society in Spain, with a mean 
annual cost per patient of a6710. Direct costs represent 81.2% of total costs.
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OBJECTIVES: Neuromuscular disorders (NMDs) are chronic devastating diseases. 
The objective of this multicenter cross-sectional study was to evaluate cost of illness 
in three NMD in Germany. METHODS: A cohort of 107 patients with Amyotrophic 
Lateral Sclerosis (ALS, n  46), Facioscapulohumeral Muscular Dystrophy (FSHD, n 
 20) or Myasthenia Gravis (MG, n  41) were recruited consecutively in seven centers 
in Germany. The health-economic data were collected using a “bottom-up” approach 
consisting of comprehensive questionnaires and patient diaries. Bootstrap 95% conﬁ-
dence intervals were calculated for cost data. Cost-driving factors were identiﬁed using 
multivariate regression analysis with standard errors estimated using a bootstrap 
technique. Costs were evaluated from the German societal perspective in 2009 Euros 
(EUR). RESULTS: Total annual costs from the societal perspective were EUR 36,380 
(95% CI: 27,090–47,970) per patient in ALS, a26,240 (95% CI: 17,770–37,940) in 
FSHD and a14,950 (95% CI: 10,470–21,730) in MG. The main components of costs 
were the expenditures of health insurance and the loss of productivity of patients and 
their caregivers. Following independent cost-driving factors were identiﬁed in ALS: 
disease severity, assistance in activities of daily living (ADL), dementia and younger 
age. In FSHD, they were disease severity and assistance in ADL. Cost-drivers in MG 
were disease severity and assistance in ADL. CONCLUSIONS: Socioeconomic burden 
of NMDs in Germany is considerable. ALS was associated with highest costs among 
studied NMDs. Further studies evaluating both the health-economic and clinical 
effects of NMDs treatment as well as disease-management programs and benchmark-
ing activities are necessary.
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OBJECTIVES: Costs of Spina Biﬁda (SB) and of its prevention with folic acid have 
never been estimated in Italy. We carried out a 12-month observational multicentre, 
prospective, cost-of-illness study of the to assess direct and indirect costs of SB from 
the patient, the third-party payer (National Health Service- NHS) and the societal 
perspective. METHODS: A total of 130 patients were enrolled in this study and were 
eligible to be analyzed according to the study protocol during 2008. The study was 
conducted in three Italian centres (Milan, Rome and Parma). Inclusion criteria were: 
walking with motor impairment, walking with simple aid, walking with complex aid, 
non walking. Exclusion criteria were: patients with dorsal lesion up to D5/D6, patients 
with spina biﬁda aperta with severe comorbidity RESULTS: Mean age was 13 years 
(min.0 – max. 29 years). The mean total cost for SB, including direct and indirect 
items, was a11,351 per patient per year (58% direct cost and 42% on indirect cost). 
The cost of medical device for SB represents the most signiﬁcant item, accounting for 
38% of the total expenses. Difference on cost analysis was observed per age (a13,882 
for an age between 0–4 years), per SB severity (non walking,, a14,323) and per lesion 
(a12,103 for SB aperta). The average Cost-of-illness per year in Italy was evaluated 
in 60 million of euro. CONCLUSIONS: The estimate of the socio-economic burden 
of SP may encourage health care interventions to prevent the occurrence of the disease 
